Oncology and Therapy最新文献

{"title":"A Comprehensive Review of the Role of Zanubrutinib for Patients with Chronic Lymphocytic Leukemia.","authors":"Paolo Ghia, Jennifer R Brown, Mazyar Shadman, Clemens-Martin Wendtner","doi":"10.1007/s40487-026-00443-w","DOIUrl":"10.1007/s40487-026-00443-w","url":null,"abstract":"<p><p>The approval of ibrutinib over a decade ago introduced Bruton tyrosine kinase (BTK) inhibition as a foundational, chemotherapy-free treatment approach for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). A continuous single-agent BTK inhibitor (BTKi) or a time-limited B cell lymphoma 2 inhibitor (BCL2i)-based regimen plus an anti-CD20 monoclonal antibody or BTKi is now standard of care for CLL/SLL. Although ibrutinib offers durable remission for many patients, its use is limited by side effects associated with inhibition of kinases other than BTK (off-target effects). The second-generation BTKi zanubrutinib was developed to provide sustained BTK inhibition with greater selectivity for BTK in order to improve clinical efficacy and tolerability with minimized off-target effects. The head-to-head ALPINE study of patients with relapsed/refractory (R/R) CLL/SLL demonstrated superior efficacy with zanubrutinib versus ibrutinib, with superior overall response rates and prolonged progression-free survival (PFS), while acalabrutinib demonstrated non-inferior PFS outcomes versus ibrutinib in patients with high-risk R/R CLL/SLL. Data also showed improved safety outcomes with zanubrutinib versus ibrutinib with significantly lower rates of atrial fibrillation/flutter, and infection, and a trend toward lower rates of other adverse events associated with ibrutinib, with the exception of neutropenia. This is reflected in treatment guidelines for CLL, where zanubrutinib and the other approved second-generation BTKi, acalabrutinib, are recommended over ibrutinib owing to their superior safety profiles (particularly reduced cardiotoxicity). In this review, we consider the pharmacologic properties of zanubrutinib that differentiate it from ibrutinib and acalabrutinib, and provide a comprehensive overview of the efficacy and safety data that led to zanubrutinib monotherapy becoming a preferred therapy for a significant subgroup of patients with CLL/SLL. We also highlight trials in CLL/SLL and Richter's transformation with zanubrutinib in targeted therapy combinations that offer the potential for time-limited treatment courses.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"519-541"},"PeriodicalIF":3.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13305230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147943141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Occupational Variation in Thyroid Cancer Incidence in the Nordic Countries.","authors":"Riikka E Mäkitie, Jan I Martinsen, Sanna Lappi-Heikkinen, Johnni Hansen, Elsebeth Lynge, Jenny Selander, Ingrid S Mehlum, Jóhanna E Torfadottir, Marcin W Wojewodzic, Rayan Nikkilä, Antti Mäkitie, Eero Pukkala","doi":"10.1007/s40487-026-00438-7","DOIUrl":"10.1007/s40487-026-00438-7","url":null,"abstract":"<p><strong>Introduction: </strong>Although the rising worldwide incidence of thyroid cancer (TC) has been largely attributed to changes in diagnostic means, the full spectrum of contributing factors remains unknown. We present a comprehensive registry-based study evaluating the impact of occupational background on the risk of TC in the Nordic countries.</p><p><strong>Methods: </strong>Data were from the Nordic Occupational Cancer (NOCCA) study from the Nordic countries from 1961 to 2005. Standardized incidence ratio (SIR) of TC in each occupational category was calculated using national incidence rates as reference.</p><p><strong>Results: </strong>The NOCCA cohort includes 14.9 million people (7.5 million women (50.3%), 7.4 million men (49.7%)). In total, 23,241 TCs were recorded: 16,758 (71.9%) in women and 6483 in men. Increased SIRs were observed in female farmers (SIR 1.19; 95% CI 1.07-1.30) and male fishermen (1.32;1.06-1.62), military personnel (1.29; 0.99-1.66), and clerical workers (1.19; 1.05-1.35).</p><p><strong>Conclusion: </strong>Our results suggest an association between certain occupational backgrounds and TC. These findings may help elucidate new risk factors for TC to enable targeted diagnosis and surveillance of individuals most at risk.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"749-765"},"PeriodicalIF":3.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13304427/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147933747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology Practice.","authors":"Patrick Squires, Ke Meng, Xiaohan Hu, Vladimir Turzhitsky, Yu-Han Kao, Jennifer Stuart, Chethan Ramamurthy, Haojie Li, Ronac Mamtani","doi":"10.1007/s40487-026-00441-y","DOIUrl":"10.1007/s40487-026-00441-y","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with muscle-invasive bladder cancer (MIBC) undergoing radical cystectomy (RC) and pelvic lymph node dissection (PLND) often receive perioperative systemic therapy. However, treatment patterns are evolving with the advent of adjuvant immunotherapy. We examined recent trends in perioperative treatment management in a contemporary cohort of US patients with MIBC undergoing RC in the immunotherapy era.</p><p><strong>Methods: </strong>We conducted this retrospective, real-world study utilizing N-Power Medicine's Bladder Analytical Dataset to describe demographics, clinical characteristics, and treatment patterns among patients with MIBC who underwent RC between 2021 and 2023. Treatment patterns were further stratified by pathologic high risk of recurrence following RC (ypT2-T4a or ypN+; pT3-4a or pN+).</p><p><strong>Results: </strong>A total of 138 patients with MIBC who underwent RC were included. The majority were male (82%) and White (83%). Overall, 49% (67/138) of patients received RC without neoadjuvant or adjuvant treatment. Approximately 46% (64/138) received neoadjuvant treatment, mainly gemcitabine and cisplatin. Only 14% (20/138) of all patients received any adjuvant treatment, including 10% (14/138) who received adjuvant nivolumab. Less than 10% of patients (9.4%, 13/138) received both neoadjuvant and adjuvant treatments. Among patients with known pathological staging post-RC (n = 125), approximately half had high risk of disease recurrence (50.4%, 63/125). Among high-risk patients, 22% (14/63) received adjuvant treatment, with 19% (12/63) specifically receiving nivolumab.</p><p><strong>Conclusion: </strong>In this contemporary cohort of patients with MIBC undergoing RC, nearly half received neoadjuvant treatment whereas the use of adjuvant treatment was limited. Since Food and Drug Administration (FDA) approval, adjuvant nivolumab use was approximately 10% in the overall cohort of patients with MIBC treated with RC, and less than 20% among those with a high risk of disease recurrence.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"841-853"},"PeriodicalIF":3.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13304048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147976250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of Prostate-Specific Membrane Antigen in Salivary Gland Tumors.","authors":"Jing Di, Emmy Mbagwu, Subhasree Basu, Brent Rupnow, Tom Jorfi, Jackson Wong, Shadi A Qasem, Shaozhou Ken Tian","doi":"10.1007/s40487-025-00401-y","DOIUrl":"10.1007/s40487-025-00401-y","url":null,"abstract":"<p><strong>Introduction: </strong>Prostate-specific membrane antigen (PSMA) is a key diagnostic/prognostic, therapeutic target in prostate cancer. While PSMA expression is well established in prostate cancer, its expression is also observed in non-prostatic tissues and other tumors. PSMA expression is observed in salivary gland tumors (SGTs); however, its expression pattern is not well established. This study assessed the distribution of PSMA expression in SGT specimens.</p><p><strong>Methods: </strong>This study retrospectively analyzed archived SGT specimens. Patient records were reviewed and their formalin-embedded tumor blocks were retrieved from the pathology department files. Immunohistochemical staining and examination was performed using an antibody directed against PSMA to assess expression levels in 243 salivary gland specimens containing 126 specimens of malignant and 117 specimens of benign SGTs. PSMA staining was quantified using a modified immunohistochemical scoring method (H score; range 0-300).</p><p><strong>Results: </strong>PSMA expression was observed in both benign SGTs and malignant SGTs; however, PSMA expression in malignant SGTs was higher than in benign SGTs. PSMA was expressed in 94% (118/126) of malignant SGTs (represented as average histochemical [H_avg] score, [Havg = 95.2]), and 61% (71/117) of benign SGTs (H_avg = 37.3). Amongst malignant SGT specimens, the highest H_avg scores were observed for adenoid cystic carcinoma (H_avg = 133.7) and acinic cell carcinoma (H_avg = 133.6). Based on the modal staining intensity scoring, strong PSMA staining (staining intensity score = 3) was observed at higher rates in malignant (38%, 48/126) versus benign (18%, 21/117) SGTs.</p><p><strong>Conclusion: </strong>This study demonstrated that PSMA is commonly expressed in malignant SGTs, suggesting that PSMA could be effective for targeted imaging and therapeutics in these tumor types.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"241-252"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12992855/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145524648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Definition of Sporadic Early-Onset Invasive Solid Organ Cancers in Adults.","authors":"Savio George Barreto, Irit Ben-Aharon, Cathy Eng, Shailesh V Shrikhande, Bhawna Sirohi, Kjetil Søreide, Stephen J Pandol","doi":"10.1007/s40487-025-00405-8","DOIUrl":"10.1007/s40487-025-00405-8","url":null,"abstract":"<p><p>With a rising incidence globally, there is need to address a basic deficiency, namely, the lack of a clear definition of sporadic early-onset invasive solid organ cancers in adults. This manuscript discusses this need to have a unified understanding of what constitutes sporadic early-onset cancers in adults based on (epi)genetic, biological, and environmental influences with an aim to motivate clinicians and scientists to think about these cancers from a broader perspective when developing their own research programs.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"41-49"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12992724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145597843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for Disease Recurrence in Patients with HER2+ Early Breast Cancer and Implications for Therapy: A Narrative Review.","authors":"Marina E Cazzaniga, Luis Costa, Gilles Freyer, Joseph Gligorov, Henrik Lindman, Piotr J Wysocki, Rupert Bartsch","doi":"10.1007/s40487-025-00398-4","DOIUrl":"10.1007/s40487-025-00398-4","url":null,"abstract":"<p><p>Human epidermal growth factor receptor 2 (HER2) overexpression or amplification of the human ERBB2 oncogene occurs in approximately one-fifth of breast cancers and, of these, two-thirds are hormone receptor (HR)-positive (HR+). The introduction of HER2-targeted therapies in recent years has significantly improved survival outcomes in patients with this tumor subtype. However, disease recurrence risk is 10-30% at 5 years with a different pattern between patients with HER2+/HR+ and HER2+/HR-negative (HR-) early breast cancer, with HR+ patients having a lower risk than those with HR- disease in the first 5 years, but a slightly higher risk at 5-10 years post-surgery. This highlights a crucial need to explore the underlying mechanisms for these differences to address specific treatment needs and to optimize systemic adjuvant treatment outcomes. Therefore, this narrative review provides an overview of published data regarding the recognized factors and ongoing challenges associated with the risk of relapse in women with HER2+ early breast cancer and proposes potential adjuvant treatment strategies to minimize risk of recurrence in high-risk patients.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"95-112"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12992776/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145472035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Strategies in Metastatic Castration-Resistant Prostate Cancer: A Narrative Review of Considerations in the Post-ARTA, Post-Docetaxel Setting.","authors":"Kenrick Ng, Birth-Lynn Tyers, Aruni Ghose, Abbas Kassamali, Reem El Debri, Jonathan Shamash","doi":"10.1007/s40487-025-00412-9","DOIUrl":"10.1007/s40487-025-00412-9","url":null,"abstract":"<p><p>The management of advanced prostate cancer has evolved significantly with the advent of androgen receptor-targeted agents (ARTAs) and docetaxel, which now form the cornerstone of first-line systemic therapy in advanced disease. However, as increasing numbers of patients progress after exposure to both an ARTA and docetaxel, optimal treatment sequencing in the post-ARTA, post-docetaxel metastatic castration-resistant prostate cancer (mCRPC) setting remains an area of clinical uncertainty, with limited comparative data to guide decisions. This narrative review synthesises the current evidence surrounding treatment strategies for mCRPC in this later-line setting. Available therapeutic options include radioligand therapy (e.g. lutetium-177-PSMA-617), cabazitaxel, PARP inhibitors (particularly for patients with DNA repair gene alterations), second-line ARTAs, further chemotherapy and immunotherapeutic approaches. However, direct head-to-head trials comparing these modalities are sparse, and much of the available data comes from retrospective or subgroup analyses, necessitating a nuanced interpretation of outcomes and limitations. Beyond efficacy, this article emphasises the critical role of practical and individualised considerations in therapy selection. These include toxicity profiles, patient comorbidities and preferences, biomarker-driven stratification (e.g. BRCA status, PSMA expression, sites of metastases), and health system factors such as drug availability and reimbursement policies, which may significantly influence access to optimal care. Finally, the review provides an overview of promising emerging therapies poised to expand the treatment landscape for mCRPC. These include bispecific T cell engagers, androgen receptor degraders, and antibody-drug conjugates, which are currently under investigation in clinical trials and may soon offer new avenues for treatment beyond traditional mechanisms.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"173-187"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12992898/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146004580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness of Nivolumab + Platinum Doublet Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer in England.","authors":"Joel Russell, Mack Harris, Ariel Sun, Benjamin White, Thor-Henrik Brodtkorb, James Brockbank, Stefano Lucherini, Lien Vo, Sandra Milev","doi":"10.1007/s40487-025-00397-5","DOIUrl":"10.1007/s40487-025-00397-5","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to assess the cost-effectiveness of neoadjuvant nivolumab + platinum doublet chemotherapy (PDC) versus relevant comparators in the treatment of patients with non-metastatic (stage IB-IIIA), resectable, non-small cell lung cancer (NSCLC) in England.</p><p><strong>Methods: </strong>A four-state semi-Markov model (event-free survival, locoregional recurrence, distant metastasis, and death states) was developed. Key clinical inputs, including most transition probabilities and all health state utility inputs, were informed by data from the CheckMate-816 trial, which compared neoadjuvant nivolumab + PDC with neoadjuvant PDC. Neoadjuvant PDC, the trial comparator, is not typically used in England, so an indirect treatment comparison (ITC) estimated the relative efficacy of neoadjuvant nivolumab + PDC versus the relevant comparators. Comparators in the ITC and model were aligned with those suggested by the National Institute for Health and Care Excellence (NICE): neoadjuvant chemoradiotherapy, surgery alone, and surgery followed by adjuvant PDC. Costs were informed by standard UK sources. Cost and health outcomes were discounted by 3.5% per year.</p><p><strong>Results: </strong>Over a lifetime time horizon, neoadjuvant nivolumab + PDC was dominant versus neoadjuvant chemoradiotherapy and adjuvant PDC, generating 0.26 and 0.7 incremental quality-adjusted life-years (QALYs) while reducing costs by £1674 and £240 per patient, respectively. Neoadjuvant nivolumab + PDC was more costly than surgery alone but was highly cost-effective; its estimated incremental cost-effectiveness ratio (ICER) was £2685 per QALY gained. Sensitivity and scenario analyses confirmed that these results are robust: only one of 10 scenarios tested yielded an ICER above £20,000 (the lower limit of the NICE reimbursement threshold).</p><p><strong>Conclusion: </strong>Neoadjuvant nivolumab + PDC is a highly cost-effective treatment for nmNSCLC. The findings of this model supported positive reimbursement decisions for neoadjuvant nivolumab + PDC from NICE.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"269-290"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12992869/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145530805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor Regarding: \"Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician's Choice of Treatment in Spain\".","authors":"Kirsten J M van Nimwegen, Mustafa Oguz, Raúl Morano, Joris Diels","doi":"10.1007/s40487-026-00420-3","DOIUrl":"10.1007/s40487-026-00420-3","url":null,"abstract":"","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"423-427"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12992832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147311146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time and Resource Implications of Subcutaneous Daratumumab-Based versus Intravenous Isatuximab-Based Treatment Regimens for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible.","authors":"Emma Smith, Alessandro Camera, Alex Bird","doi":"10.1007/s40487-026-00419-w","DOIUrl":"10.1007/s40487-026-00419-w","url":null,"abstract":"<p><strong>Introduction: </strong>Multiple myeloma (MM) treatment is associated with significant healthcare provider (HCP) and patient time burden due to the frequency and duration of hospital visits for treatment. This study evaluated impacts on HCP and patient time burden of daratumumab subcutaneous (SC)-based versus isatuximab intravenous (IV)-based regimens in patients with newly diagnosed MM who are transplant ineligible.</p><p><strong>Methods: </strong>An online survey of HCPs (hemato-oncology specialists, nurse practitioners, and hospital pharmacists) was conducted in nine European countries and Egypt. Respondents provided estimates of HCP and patient time associated with individual SC and IV treatment steps. These survey data and published dosing schedules informed development of a resource utilization model to compare overall time burden for SC and IV regimens over a 2-year cumulative period.</p><p><strong>Results: </strong>HCPs reported savings in median active working time per treatment visit for steps before, during and after administration of daratumumab SC versus isatuximab IV treatments, with a total median saving of up to 135 min (39.1% reduction). HCPs also reported less median patient time per visit with daratumumab SC versus isatuximab IV treatments, with a total median saving of up to 115 min (27.1% reduction). Over 2 years, reduced time for SC versus IV administration, coupled with the less frequent dosing schedule for daratumumab versus isatuximab, resulted in marked time savings for HCPs and patients with D-Rd SC (HCPs: 221 h saved [64.2% reduction]; patients: 224 h [61.2% reduction]), D-VRd SC (HCPs: 157 h [45.6% reduction]; patients: 149 h [40.7% reduction]), and D-VMP SC (HCPs: 147 h [42.7% reduction]; patients: 140 h [38.3% reduction]) versus Isa-VRd IV.</p><p><strong>Conclusions: </strong>This study demonstrated notable time savings with daratumumab SC-based versus isatuximab IV-based regimens in patients with newly diagnosed MM who are transplant ineligible based on SC versus IV administration and less frequent daratumumab dosing.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"409-422"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12992721/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146228954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}